Compare CATY & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CATY | ERAS |
|---|---|---|
| Founded | 1962 | 2018 |
| Country | United States | United States |
| Employees | 1268 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | 1996 | 2021 |
| Metric | CATY | ERAS |
|---|---|---|
| Price | $63.08 | $19.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $52.50 | $14.25 |
| AVG Volume (30 Days) | 556.6K | ★ 5.6M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | 14.94 | ★ 36.23 |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $53,793,000.00 | N/A |
| Revenue This Year | $20.37 | N/A |
| Revenue Next Year | $5.41 | N/A |
| P/E Ratio | $48.47 | ★ N/A |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $43.69 | $1.33 |
| 52 Week High | $63.91 | $24.28 |
| Indicator | CATY | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 59.18 | 59.23 |
| Support Level | $59.87 | $17.63 |
| Resistance Level | $63.81 | $21.60 |
| Average True Range (ATR) | 1.19 | 1.29 |
| MACD | -0.10 | -0.16 |
| Stochastic Oscillator | 77.97 | 41.03 |
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credit, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities, and advisory services.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.